Evidence map›Paper›PMID 40576825›Full record

ReviewJournal of molecular medicine (Berlin, Germany)2025

The molecular landscape of glioblastoma-associated epilepsy.

Thamiris Becker Scheffel, Fernando Mendonça Diz, Andréa Wieck, Karine Rech Begnini, Jaderson Costa da Costa

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Thamiris Becker ScheffelBrain Institute (BraIns), Pontifical Catholic University of Rio Grande Do Sul, Avenida Ipiranga, 6690, Partenon, Porto Alegre, 90610-000, Brazil. t.scheffel@edu.pucrs.br.ORCID http://orcid.org/0000-0003-3787-568X
Fernando Mendonça DizBrain Institute (BraIns), Pontifical Catholic University of Rio Grande Do Sul, Avenida Ipiranga, 6690, Partenon, Porto Alegre, 90610-000, Brazil.
Andréa WieckBrain Institute (BraIns), Pontifical Catholic University of Rio Grande Do Sul, Avenida Ipiranga, 6690, Partenon, Porto Alegre, 90610-000, Brazil.
Karine Rech BegniniDepartment of Biophysics, Institute of Biosciences, Federal University of Rio Grande do Sul, Avenida Bento Gonçalves 9500, Porto Alegre, 91501-970, Brazil.
Jaderson Costa da CostaBrain Institute (BraIns), Pontifical Catholic University of Rio Grande Do Sul, Avenida Ipiranga, 6690, Partenon, Porto Alegre, 90610-000, Brazil. jcc@pucrs.br.

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 23/2551-0001899-3
6 · The paper itself

Abstract

Glioblastoma (GBM) is the most prevalent and aggressive primary brain tumor. Tumor-associated epilepsy is a clinical challenge in GBM patients, with seizures being a common symptom and reflecting complex interactions within the tumor microenvironment. This review highlights key molecular mechanisms behind GBM-associated epilepsy, including genetic alterations, increased glutamate release, ion channel dysfunction, and inflammation. These factors disrupt the surrounding neurons, promoting seizures. Shared pathways between epilepsy and GBM, such as those involved in synaptic signaling and immune responses, present potential therapeutic targets. Antiseizure drugs remain the primary treatment, with newer options like perampanel showing promise in reducing seizures and possibly influencing tumor growth. Understanding the interplay between epilepsy and GBM at the molecular level is crucial for advancing personalized treatment strategies and improving outcomes for patients.

Indexed as

Brain NeoplasmsEpilepsyGlioblastomaAnimalsAnticonvulsantsHumansTumor MicroenvironmentAnticonvulsantsAntiseizure medicationGenetic alterationGliomaMutationSeizure

Identifiers

PMID40576825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.